Related Experiment Video
Updated: May 27, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Availability of insulin pump therapy in clinical practice
B-M Carlsson1, P Nord Andersson, J Alnervik
1Diabetes Section of Medicine, SÄS-Hospital Organization, Skene, Uddevalla, Sweden.
Diabetic Medicine : a Journal of the British Diabetic Association
|November 5, 2011
Summary
Insulin pump therapy availability varies by clinic and patient demographics. Younger women with fewer complications are more likely to use insulin pumps, indicating potential disparities in access to this diabetes management technology.
Area of Science:
- Endocrinology
- Diabetes Management
- Health Services Research
Background:
- Insulin pump therapy is a key treatment for Type 1 diabetes.
- Understanding factors influencing its adoption is crucial for equitable care.
Purpose of the Study:
- To investigate the availability and uptake of insulin pump therapy in Type 1 diabetes patients.
- To identify patient and clinic-level factors associated with insulin pump use.
Main Methods:
- Analysis of a cohort of 7224 Type 1 diabetes patients.
- Logistic and Cox regression models to assess predictors of insulin pump initiation.
Main Results:
- Insulin pump use varied significantly by outpatient clinic and patient sex.
- Younger age, female sex, higher HbA1c, lower creatinine, and specific insulin dosing patterns were associated with increased pump adoption.
- Women were 1.5 times more likely to start insulin pump therapy.
Conclusions:
- Significant variation in insulin pump therapy availability exists across clinics.
- Younger patients and women are more likely to use insulin pumps, suggesting potential access disparities.
- Further research is needed to optimize insulin pump availability and ensure equitable access.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...